# A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

> **NCT01288079** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 145 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** TC-5214
- **DRUG:** Duloxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01288079
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2012-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288079, "A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01288079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*